Drug Repurposing Applications to Overcome Male Predominance via Targeting G2/M Checkpoint in Human Esophageal Squamous Cell Carcinoma

Drug Repurposing Applications to Overcome Male Predominance via Targeting G2/M Checkpoint in Human Esophageal Squamous Cell Carcinoma

Esophageal squamous cell carcinoma (ESCC) is strongly characterized by a male predominance with higher mortality rates and worse responses to treatment in males versus females. Despite the role of sex hormones, other causes that may contribute to sex bias in ESCC remain largely unknown, especially a...

Full description

Bibliographic Details
Main Authors:	Yin Yin, Xiao Yu, Riyue Feng, Yang Li, Yahui Zhao, Zhihua Liu
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Series:	Cancers
Subjects:	esophageal squamous cell carcinoma sex bias aging G2/M checkpoint drug repurposing
Online Access:	https://www.mdpi.com/2072-6694/14/23/5854

Similar Items

Considerations and challenges for sex-aware drug repurposing
by: Jennifer L. Fisher, et al.
Published: (2022-03-01)

Research Progress of Predictive Markers for Efficacy of Immune Checkpoint Inhibitors for Esophageal Squamous Cell Carcinoma
by: CHEN Rongshan, et al.
Published: (2022-12-01)

Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
by: Jiang-Qiong Huang, et al.
Published: (2024-03-01)

Drug repositioning for esophageal squamous cell carcinoma
by: Adam N. Bennett, et al.
Published: (2022-09-01)

Transcriptomics based multi-dimensional characterization and drug screen in esophageal squamous cell carcinoma
by: Yin Li, et al.
Published: (2021-08-01)

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
by: Yi-Min Gu, et al.
Published: (2021-12-01)

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
by: Qingxu Liu, et al.
Published: (2023-11-01)

Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma
by: Ying Li, et al.
Published: (2022-12-01)

Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
by: Yue Ma, et al.
Published: (2022-11-01)

Elevated TAB182 enhances the radioresistance of esophageal squamous cell carcinoma through G2‐M checkpoint modulation
by: Yuandong Cao, et al.
Published: (2021-05-01)

Successful immune checkpoint inhibitor‐based rechallenge in a patient with advanced esophageal squamous cell cancer: A case report
by: Yanhong Yao, et al.
Published: (2022-02-01)

Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: Perioperative and Survival Outcomes
by: Xiao Ma, et al.
Published: (2022-06-01)

Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data
by: Kim Y, et al.
Published: (2023-05-01)

Characterization of Esophageal Microbiota in Patients With Esophagitis and Esophageal Squamous Cell Carcinoma
by: Zongdan Jiang, et al.
Published: (2021-11-01)

Comparative transcriptome characterization of esophageal squamous cell carcinoma and adenocarcinoma
by: Xianfeng Li, et al.
Published: (2023-01-01)

Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
by: Ruixi Wang, et al.
Published: (2022-10-01)

Perioperative immunotherapy for esophageal squamous cell carcinoma
by: Dan D. Wei, et al.
Published: (2024-02-01)

Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
by: Xavier Thuru, et al.
Published: (2022-07-01)

Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions
by: Mengjie Jiang, et al.
Published: (2023-05-01)

Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions
by: Mengjie Jiang, et al.
Published: (2023-05-01)

Overview of Risk Factors for Esophageal Squamous Cell Carcinoma in China
by: Erica Conway, et al.
Published: (2023-11-01)

Esophageal squamous cell carcinoma presenting as a submucosal tumor
by: Lin Yang, et al.
Published: (2023-08-01)

Identification of a Prognostic Immune Signature for Esophageal Squamous Cell Carcinoma to Predict Survival and Inflammatory Landscapes
by: Chaoqi Zhang, et al.
Published: (2020-12-01)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
by: Huilai Lv, et al.
Published: (2022-04-01)

Impact of sex on the prognosis of patients with esophageal squamous cell cancer underwent definitive radiotherapy: a propensity score-matched analysis
by: He-San Luo, et al.
Published: (2019-05-01)

Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study
by: Zhao J, et al.
Published: (2023-08-01)

Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience
by: Ming-Wei Kao, et al.
Published: (2023-04-01)

Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy
by: Kenneth K. W. To, et al.
Published: (2023-08-01)

Inducing multiple antibodies to treat squamous cell esophageal carcinoma
by: Isamu Hoshino, et al.
Published: (2020-10-01)

Cross sectional study of serum selenium concentration and esophageal squamous dysplasia in western Kenya
by: Natalie R. Pritchett, et al.
Published: (2017-12-01)

Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives
by: Yusuke Nagata, et al.
Published: (2022-11-01)

Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer
by: Jhe‐Cyuan Guo, et al.
Published: (2023-08-01)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
by: Huilai Lv, et al.
Published: (2023-01-01)

B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
by: Jhe-Cyuan Guo, et al.
Published: (2022-06-01)

The combination of novel immune checkpoints HHLA2 and ICOSLG: A new system to predict survival and immune features in esophageal squamous cell carcinoma
by: Chaoqi Zhang, et al.
Published: (2022-03-01)

Esophageal Squamous Cell Carcinoma with Marked Eosinophil Infiltration
by: Minoru Fukuchi, et al.
Published: (2011-11-01)

Neoadjuvant Carboplatin/Paclitaxel versus 5-Fluorouracil/Cisplatin in Combination with Radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Comparative Study
by: Xing Gao, et al.
Published: (2022-05-01)

Clinicopathological and genomic features of superficial esophageal squamous cell carcinomas in nondrinker, nonsmoker females
by: Motomitsu Fukuhara, et al.
Published: (2024-02-01)

Esophageal Pleural Fistula in Esophageal Squamous Cell Carcinoma: A Diagnostic Challenge
by: Naghmeh Salarieh, et al.
Published: (2023-08-01)

Right Compared With Left Thoracic Approach Esophagectomy for Patients With Middle Esophageal Squamous Cell Carcinoma
by: Yan Zheng, et al.
Published: (2020-10-01)